We compared the impact of 3 confounding adjustment procedures-covariate-adjusted regression, propensity score regression, and high-dimensional propensity score regression-to assess the effects of selected asthma controller medication use (leukotriene antagonists and inhaled corticosteroids) on the following 4 asthma-related adverse outcomes: emergency department visits, hospitalizations, oral corticosteroid use, and the composite outcome of these. We examined a cohort of 24,680 new users who were 4-17 years of age at the incident dispensing from the Population-Based Effectiveness in Asthma and Lung Diseases (PEAL) Network of 5 commercial health plans and TennCare, the Tennessee Medicaid program, during the period January 1, 2004, to December 31, 2010. The 3 methods yielded similar results, indicating that pediatric patients treated with leukotriene antagonists were no more likely than those treated with inhaled corticosteroids to experience adverse outcomes. Children in the TennCare population who had a diagnosis of allergic rhinitis and who then initiated the use of leukotriene antagonists were less likely to experience an asthma-related emergency department visit. A plausible explanation is that our data set is large enough that the 2 advanced propensity score-based analyses do not have advantages over the traditional covariate-adjusted regression approach. We provide important observations on how to correctly apply the methods in observational data analysis and suggest statistical research areas that need more work to guide implementation.
Although randomized clinical trials are widely regarded as providing the highest level of evidence for answering questions related to clinical efficacy, they are often criticized for lacking generalizability (1) . Pragmatic clinical trials that are more suited to answering broader questions of effectiveness are gaining in popularity, but many investigators still rely on large observational studies to assess the real-world impact of various clinical interventions and lifestyle behaviors (2) . Deriving causal inference from observational data, however, is challenging because of the inherent confounding issues (3) . Therefore, an appropriate analysis of observational data requires careful control for potential confounders, and multiple statistical methods have been developed to accomplish this (4) (5) (6) .
Covariate-adjusted (CA) regression is the classic confounding adjustment method, which adjusts for potential confounders by directly including them in the regression model (7) . An alternative method is propensity score (PS) analysis (8) . The PS is defined as the conditional probability of receiving the exposure of interest given measured covariates (5) . The PS is effectively a summary score that incorporates information from multiple covariates. The high-dimensional propensity score (hdPS) technique (6) builds upon the PS approach by ascertaining and selecting additional empirical covariates from electronic health care databases and then using these empirical covariates jointly with the predefined covariates in PS estimation to enhance confounding adjustment. Nevertheless, despite the increasing use of the PS-based methods and a growing amount of advanced methodological research in this area (9, 10) , knowledge of how to correctly apply these methods and their potential impact on observational epidemiology is still limited (11, 12) .
We explored and compared CA methods, PS adjustment, and hdPS adjustment as part of a comparative effectiveness study of the relative impact of 2 major classes of controller medications for asthma-leukotriene antagonists (LTRAs) versus inhaled corticosteroids (ICSs)-among a cohort of pediatric asthma patients in the Population-Based Effectiveness in Asthma and Lung Diseases (PEAL) Network population. The primary outcomes of interest were asthma-related exacerbations as assessed by emergency department visits, hospitalizations, and use of oral corticosteroids. National guidelines recommend the use of ICSs as first-line controller therapy rather than LTRAs, and randomized clinical trials (13) (14) (15) (16) suggest that patients using ICSs are less likely to experience asthma-related exacerbations than patients using LTRAs. Nevertheless, anecdotal evidence suggests that LTRAs are frequently used as first-line controller therapy rather than ICSs, because adherence to oral medicines (i.e., LTRAs) seems to be better than adherence to inhalers (i.e., ICSs), and some families may prefer LTRAs because of concerns that inhaled steroids may stunt a child's growth. Using this example, we review the strengths and weaknesses of the 3 methods, discuss lessons learned from the implementation process, and identify knowledge gaps.
METHODS

Study design and population
The PEAL Network includes TennCare, the Tennessee Medicaid program, and the following 5 commercial health plans: Harvard Pilgrim Health Care, HealthPartners (Minneapolis, Minnesota), Kaiser Permanente (KP) Northern California, KP Georgia, and KP Northwest (17) . The PEAL data warehouse includes information on individual demographic characteristics, enrollment records, health care utilization, and medication dispensing records (18, 19) for individuals with lung disease, as well as electronic medical records for a subset of these individuals.
Individuals were identified from claims records and electronic medical records and were potentially eligible for inclusion in the PEAL asthma population if they had any International Classification of Diseases, Ninth Revision, discharge diagnosis of code for asthma (code 493.xx) during an acute inpatient hospital stay, emergency department visit, ambulatory visit, or nonacute institutional stay during the period January 1, 2004, to December 31, 2010 . This time window varied for each site by up to 1 year on the basis of data availability. Individuals were excluded if they had a diagnosis of cystic fibrosis, immunodeficiency, bronchiectasis, hereditary or degenerative diseases of the central nervous system, psychoses, mental retardation, congestive heart failure, pulmonary hypertension, or pulmonary embolism based on International Classification of Diseases, Ninth Revision, codes.
We identified 218,019 individuals in the PEAL Network who had at least 1 qualified asthma controller medication dispensing, meaning that, in the 12-month period prior to the dispensing date, they had continuous enrollment and uncontrolled asthma, which is defined as having at least 1 eligible health care encounter (hospitalization, emergency department visit, or dispensing of oral corticosteroids of 3 days or more). Patients who were dispensed individual ICSs and long-acting β agonist inhalers on the same day were placed in the ICS/long-acting β agonist group. We define the earliest dispensing date among all qualified dispensings as the index date and the date 12 months prior to this as the baseline period. We excluded 13,830 individuals who did not initiate monotherapy (or ICSs/long-acting β agonists) of 1 of the controller medications of interest on the index date, and 204,189 individuals remained. Of the 204,189 individuals, 84,044 patients were incident users (no controller medication use during the 12-month baseline period). In this analysis, we focus on the 24,680 pediatric patients aged 4-17 years on the index date who were incident users of either LTRAs (29%) or an ICS (71%).
Study outcomes
We examined the relative impact of LTRA versus ICS use on time from index date to first occurrence of the following: an asthma-related emergency department visit, an asthmarelated hospitalization, dispensing of an oral corticosteroid burst pack, or any of these (composite outcome). The followup time was censored at disenrollment, 30 days after a patient augmented treatment (e.g., switched from LTRA to ICS or vice versa or added a long-acting β agonist to an ICS), or 365 days after the index date, whichever came first. We attributed all outcomes that occurred during the 30 days after augmentation to the initial controller medication, because medication augmentation is typically a sign of poor disease control by the initial controller medication and, thus, the adverse outcomes occurring soon after the augmentation should be attributed to the failure of the initial medication, not the newly augmented medication. We censored patients at 30 days after medication augmentation because it takes approximately 30 days for controller medications to become beneficial (20) .
Time-varying adherence measure
We calculated a time-varying adherence measure for the initiated medication as the proportion of days covered (PDC) (21) based on a moving preceding 30-day window (i.e., the PDC on day t was calculated on the basis of the [t -31, t -1] window). We then dichotomized values as either ≥0.75 or <0.75 (22) . Because the PDC methodology assumes that all medications are used as directed, all participants start with a guaranteed minimum of 30 days of good adherence. Any individuals who experienced the outcome of interest during this period were excluded from the analysis (i.e., the analysis was conditional on "survival" for the first 30 days).
Covariates
For the CA analysis, we included a variety of potential confounders, including patient demographic characteristics, prior asthma-related health care utilization, rescue medication use, and chronic medical conditions ( Table 1 ). The claimsderived variables were created on the basis of clinical expertise as surrogate measures of asthma disease severity and level of control. These same variables were used to estimate the PSs for the PS analysis. The hdPS analysis further drew on a varying number of empirical covariates from the PEAL database. We describe the process below.
Confounding adjustment methods
We used Cox regression (4) as the base model to analyze time-to-event outcomes adjusting for the time-varying PDC measure. We considered the following 3 methods that were used jointly with the Cox regression to adjust for baseline confounding: CA regression (4), PS regression (23) , and hdPS regression (6) .
CA regression. The CA approach adjusts for the covariates directly in the Cox regression model. Specifically, in this application, let A(t) denote the dichotomized PDC measure on day t, and let E denote the binary exposure variable (E = 1 for LTRA and E = 0 for ICS). In the CA analysis, we impose the following model for the hazard rate for each of the 4 outcomes:
where X denotes the vector of predefined covariates listed in Table 1 . Exp(β 1 + β 2 ) denotes the parameter of interest, the Table continues 650 Li et al.
hazard ratio between LTRA versus ICS when both controller medications were adhered to. The validity of the CA analysis requires that the imposed model 1 is correct. PS regression. In this application, the PS is defined as the conditional probability of receiving LTRA given the predefined covariates (Pr(E = 1|X)). The PSs are unknown and were estimated with a logistic regression model regressing E on the predefined covariates X. Then the estimated PSs were adjusted for as quintile categories in the Cox regression, replacing the covariate vector X. The exposure variable E and the time-varying adherence measure A(t) were adjusted for in the same manner as in model 1.
The PS analysis may be biased if 1) the PS model is wrong, or 2) as with any regression analysis, the PS regression did not adjust for the PS appropriately (e.g., if the log of the hazard rate is in fact a linear function of PS instead of a step function (23)). Nevertheless, the PS analysis has a number of advantages. First, the PS model typically can include more covariates and more complex functional forms, such as higher order polynomials or interactions, than can the CA regression model because the number of exposed individuals is typically much larger than the number of adverse outcomes. Sometimes, there is prior knowledge of how physicians/ patients made treatment selections, which can aid in PS modeling. Second, the goodness-of-fit of the imposed PS model can be assessed by comparing the distributions of the predefined covariates X between the exposure groups after adjusting for the estimated PSs (24) . The confounders should be distributed equally between the exposure groups after adjustment. Third, the use of a single PS for confounding adjustment can lead to simpler regression models that are potentially easier to interpret and less subject to statistical issues such as incorrect functional forms or covariate collinearity. Moreover, PSs facilitate an often overlooked requirement for valid covariate adjustment: overlapping covariate values, or "common support," across the exposure groups (25) . Common support is required to prevent extrapolation beyond the range of the data. Covariate overlap is absent, for example, when 1 group includes individuals aged 45-65 years but the other is limited to those aged 45-55 years. Although it is difficult to assess multidimensional overlap among all of the covariates, it is relatively simple, as demonstrated below, to assess overlap in the PS.
HdPS regression. The hdPS analysis is identical to the traditional PS analysis, with the exception that the PSs generated in the hdPS analysis were estimated using both the predefined covariates X and a list of empirical covariates (6) derived from the PEAL database. These empirical covariates were derived and selected using a semiautomatic algorithm (26, 27) on the basis of their associations with the outcome. Thus, the set of empirical covariates varies by outcome. In our case, we used the following 7 data dimensions to create the list of empirical covariates: inpatient diagnosis, inpatient procedure, outpatient diagnosis, outpatient procedure, emergency department diagnosis, emergency department procedure, and medication dispensing during the 12 months prior to the index date. We capped the number of empirical covariates at floor (n / 50 − r), where n is the number of individuals, r is the number of main effect terms from the predefined covariates, and the floor function takes the biggest integer that is smaller than or equal to (n / 50 -r) to ensure that there were at least 50 individuals per main term in the logistic regression model for PS estimation to avoid overfitting (28) .
Statistical analysis
Because of the striking differences in participant demographic characteristics, prior health care utilization, and use of LTRAs (Table 1 ) between the 5 commercial health plan and TennCare populations, we conducted separate analyses for these 2 populations. For each sample, we also conducted separate analyses for individuals who did or did not have a diagnosis of allergic rhinitis in the baseline period, because LTRAs could be used to treat both allergic rhinitis and persistent asthma (29) and because symptoms from allergic rhinitis could trigger asthma-related exacerbations (30) . We defined the allergic rhinitis variable on the basis of the diagnosis codes during the baseline period. Thus, prior allergic rhinitis is a pretreatment variable and should not be on the causal pathway between the exposure and the outcome.
We calculated the PSs separately for the 3 KP sites (KP Georgia, KP Northern California, and KP Northwest) as a group and for the 2 remaining health plans (Harvard Pilgrim Health Care and HealthPartners) as a group to reflect the different prevalence rates of LTRA use in these 2 groups. For each group (KP sites, non-KP sites, and TennCare) we estimated the PSs separately for those with and without a diagnosis of allergic rhinitis. The number of empirical covariates included in PS estimation ranged from 0 to 144.
We assessed covariate balance, both before and after PS adjustment, using the standardized difference, which is defined as the difference in means or proportions divided by the pooled standard deviation (31) . The standardized difference is insensitive to sample size and, thus, is more appropriate than a Student's t test or a χ 2 test when the overall sample size is large (31) . A standardized difference of 0.10 or greater indicates the existence of some imbalance (31) .
Theoretical guidance on determining the common support is not available, and we determined the common support region on an ad hoc basis. We plotted smoothed histograms of the PSs within each group on the basis of kernel density estimates. These plots show values of the PS for which each exposure group has at least a few observations, and we defined common support on that basis. We selected a range of PSs over which the estimated density estimates were 2% or greater. Observations outside the common support were excluded from further analyses. The selection of 2% as the cutoff point was arbitrary, so we repeated the analyses with a higher cutoff of 4%. The number of individuals within the common support regions further decreased, but results were similar (data not shown). All analyses were performed in SAS, version 9.3, software (SAS Institute, Inc., Cary, North Carolina).
RESULTS
We included data from 24,680 individuals, including 14,791 from the 5 commercial health plans and 9,889 from TennCare. The use of LTRA varied widely, with high use observed among TennCare participants (59.3%), low use among those from the 3 KP sites (3.7%), and moderate use among those from the 2 non-KP sites (21.4%). The use of LTRA was also higher among those with a prior diagnosis of allergic rhinitis than among those without allergic rhinitis balance was improved on race, health plan, prior health care use, and prior diagnosis of allergic rhinitis as the standardized difference values decreased after PS adjustment. The improvement was greater among the TennCare population with a much higher proportion of LTRA users. The hdPSs improved covariate balance in a similar manner (data not shown). Figures 1-3 depict PS kernel density estimates among LTRA and ICS users in each of the 6 subgroups defined by health plan (3 KP sites, 2 non-KP sites, and TennCare) and diagnosis of allergic rhinitis. As seen in the figure, the kernel densities were fairly similar for the 2 medication arms within each population subgroup. The dotted vertical lines in each panel define the region of common support and exclude approximately 10% of patients. Table 2 presents the crude incidence rates ( per 100,000 person-days) of the 4 asthma-related adverse outcomes and the associated 95% confidence intervals among the LTRA and ICS users. Table 3 provides results from the 3 adjustment procedures (i.e., the hazard ratio estimates among compliers). To assess the impact of restricting analyses to the common support region, we present results for the CA regression both for the full cohort and for the PS common support restricted subsample. Results are shown by care delivery model (commercial health plans vs. TennCare) and by allergic rhinitis status.
Hazard ratio estimates were generally similar across the 4 adjustment procedures, and significant results were seen consistently in all 4 regression models. All of the confidence intervals overlapped considerably. We also observed no evidence that the hazard ratio estimates from any particular analytical approach were consistently higher or lower than those from other approaches. It is true, however, that the restricted CA, PS, and hdPS analyses had consistently higher standard error estimates for log(hazard ratio) than the CA analyses fit to the full cohort (mostly by a factor of <20%). The point and interval estimates were slightly unstable for the hospitalization outcome, likely because of the small number of events. The results from PS regression and hdPS regression remained similar (data not shown) in 2 additional analyses in which we adjusted for PSs 1) via the linear and quadratic terms of the continuous PS, and 2) via the quintile categorization and the linear and quadratic terms of the continuous PS. Among patients with a diagnosis of allergic rhinitis, individuals in TennCare who were treated with LTRAs were less likely to experience emergency department visits (hazard ratio = 0.43, 95% confidence interval: 0.21, 0.88 from CA regression on all study individuals) compared with individuals treated with ICS. For all other comparison groups, whether individuals had allergic rhinitis or not, individuals treated with LTRA were just as likely to experience emergency department visits or hospitalizations or to need oral corticosteroids as individuals treated with ICS. Refer to our companion paper for more detailed discussion on the clinical implications of the results (A.C.W., Harvard Pilgrim Health Care Institute and Children's Hospital, unpublished manuscript).
DISCUSSION
We examined the impact of 3 confounding adjustment methods (CA regression, PS regression, and hdPS regression) in an observational study of the impact of asthma controller medication use (LTRA vs. ICS) on 4 asthma-related adverse outcomes.
In each of 4 population subgroups defined by insurance type (commercial health plans vs. TennCare) and allergic rhinitis diagnosis, these 3 adjustment approaches gave essentially equivalent results with no consistent differences in point estimates and highly overlapping confidence intervals. Consistency in results brings reassurance about appropriate model selection and indicates that the hdPS approach did not identify any additional highly influential confounder.
Our finding that LTRAs may be just as effective as ICSs in preventing asthma-related exacerbations in real-life settings is contrary to the results of randomized clinical trials in which patients using ICSs were found to experience fewer asthma-related exacerbations than patients using LTRAs (15) . One possible reason for our findings is that additional nonadherence beyond that adjusted for by the time-varying PDC played a role (13) . Alternatively, persistent unmeasured confounding could also explain our results. We ascertained the predefined and empirical covariates from electronic health care databases that were designed for nonresearch purposes and, thus, may have limited information on confounders such that all adjustment procedures are subject to residual bias due to uncontrolled confounding. In Tenncare patients with a diagnosis of allergic rhinitis, we found that those who were treated with LTRAs were less likely to experience asthma-related exacerbations. This result is consistent with prior studies (32) and may be due to the use of LTRAs as treatment for allergic rhinitis, which can be a trigger of asthma-related exacerbations. Interestingly, this finding was not observed in the commercial health plan population. When comparing TennCare with commercial health plan populations, 2 important distinctions should be noted. First, for the most part, children with public insurance are more likely than those who are privately insured to use the emergency department for nonurgent conditions or, in this case, for minor asthma exacerbations. Thus, in the TennCare population, a patient who experiences an asthma-related emergency department visit is likely to be less ill than a patient in the commercial health plan population who had an emergency department visit. Also, TennCare patients were more likely than commercial health plan patients to be prescribed an LTRA. One possible reason is that adherence to oral medications, such as LTRAs, may be higher than adherence to inhaled medications, such as ICSs. The increased effectiveness of LTRAs in the TennCare population may reflect real differences in "effectiveness" between the cohorts (because of underlying differences in asthma severity and health-seeking behaviors) or increased power to detect an effect (because of increased number of LTRA-exposed individuals); alternatively, it may have been a spurious finding due to residual confounding bias or imperfect adjustment of medication adherence.
It is unclear how generalizable our findings are to other data sets or analytical questions. Nevertheless, the PS and hdPS analyses have been found to be useful in other studies (6, (33) (34) (35) . We expect these approaches to be used more commonly because of the analytical advantages we described above and the increasingly available electronic health care data. Thus, our critical observations on how to correctly apply these methods in observational data analyses are important. We describe the 4 most important observations below.
First, even though accounting for covariate overlap did not have a substantial impact in this specific application, likely because covariate nonoverlap was minimal, we recommend adopting this as a routine analysis step, even for traditional CA methods. The validity of comparative effectiveness analysis is suspect when covariate overlap is absent. Common support is required to prevent extrapolation beyond the range of the data. We found in a different application that failure to assess covariate overlap can result in substantially different results and conclusions (36) . However, theoretical guidance on determining the common support is not available, at least to the best of our knowledge. We determined the common support region on an ad hoc basis. In the absence of objective, evidence-based guidelines, we suggest varying the cutoff points for the common support selection and assessing the robustness of analytical results to such changes.
Second, it is important to identify confounders that have a strong impact on medication use patterns and to conduct separate logistic regression models among the subgroups defined by the confounders. In our example, allergic rhinitis and the health plans played this role. A combined logistic regression model adjusting for the confounders as independent variables will not suffice for proper PS estimation and overlap assessment. For example, in this application, had we pooled all 5 commercial health plans, adjusted for health plan as a covariate in the PS model, and estimated the PS kernel densities within all 5 health plans, the PS density estimates for the non-KP sites would have been so small (because of the much larger number of patients from the KP sites) that all of them would have fallen outside the common support region and hence been excluded from subsequent analyses.
Thus, for the purpose of common support selection, it is important to separate individuals with different PS ranges.
Third, capping the number of empirical covariates may be important. During our data analyses, we discovered a recent study that was conducted by a group of researchers including the inventors of the hdPS approach (28) . This study suggests capping the number of empirical covariates such that there are at least 50 individuals per main effect term in the logistic regression model. We adopted this recommendation because we agree that it is important to determine the number of empirical covariates in the hdPS analysis to avoid overfitting in the logistic regression model for hdPS estimation. Nonetheless, we think this recommendation needs to be evaluated more thoroughly.
Fourth, although we tried to better understand the results across different methods, we realize that the current hdPS program does not output the diagnosis, procedure, or national drug codes from which the selected empirical covariates were derived. It prevents the investigators from modifying the empirical covariate definitions on the basis of their clinical expertise, which may result in better performance of the hdPS approach.
The administrative claims databases we used have limitations, including the lack of detailed information on clinical measures of disease severity and level of control, no medication order data, potential missing data from health care encounters and medication dispensing not captured by the claims systems, loss to follow-up due to patients switching health plans, and claims coding errors. However, these issues are not unique to the PEAL database. Another limitation of our analyses is that the use of asthma controller medication is not a 1-time decision. Parents of pediatric asthma patients may often consider whether to stop, resume, or decrease the frequency of controller medication use on the basis of multiple factors, including the level of disease control while their children are on therapy. Some of these factors may affect the risk of exacerbation outcomes. The electronic health care databases, unfortunately, have very limited information on the level of disease control and, thus, do not allow us to adjust for time-varying confounding appropriately. Hence, we used the 3 confounding adjustment methods only for the purpose of controlling for baseline confounding. We then used the timevarying PDC measure to adjust for adherence because we were interested in comparing the effects of the controller medications when patients were adhering to the medications.
In summary, confounding adjustment in observational data is challenging. In comparing 3 approaches, we found that the results in our application were robust to method selection and implementation factors. Our main findings are important observations on how to correctly apply these methods in observational data analysis. In addition, we have identified key areas in which more work is needed to guide implementation.
